N/A
N=50
Progesterone for Postpartum Cocaine Relapse
Cocaine Abuse · Cocaine Dependence
Bottom Line
View on ClinicalTrials.gov: NCT01249274 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcome: Primary: Mean Number of Days Per Week of Cocaine Use — 0.41; 1.15; 0.43; 1.01 number of days per week of cocaine use — p=0.010
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Progesterone (Drug); Placebo (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Yale University
- Primary completion
- Jul 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Number of Days Per Week of Cocaine Use |
0.41; 1.15; 0.43; 1.01; 0.45; 0.89 | 0.010 sig |
| PRIMARY Number of Days of Cocaine Use Between 12 Week Visits & the 3 Month Follow up |
0.5200; 1.6800; 0.2860; 0.05550; 12.8472; 1.3659 | 0.003 sig |
| PRIMARY Proportion of Positive Urine Samples Per Week |
0.2400; 0.1582; 0.3173; 0.1904; 0.3952; 0.2246 | 0.75 |
| PRIMARY Proportion of Positive Urine Samples Per Week |
0.2400; 0.1582; 0.3173; 0.1904; 0.3952; 0.2246 | 0.75 |
| SECONDARY Overall Comparison of Adverse Events Between Women in Placebo and Progesterone Group |
11; 15 | 0.1030 |
| SECONDARY Cocaine Craving (Measured Weekly Using CCQ-Brief) |
1.5630; 1.6752; 1.5456; 1.6532; 1.5285; 1.6316 | 0.9116 |
| SECONDARY Depression (Measured Weekly Using Edinburgh Postnatal Depression Scale (EPDS)) |
10.84; 11.08; 8.05; 8.61; 8.57; 6.65 | — |
| SECONDARY Salivary Progesterone Concentrations |
165.94; 797.26; 189.38; 1580.95; 124.30; 1771.07 | — |
Summary
The investigators propose a placebo-controlled, randomized clinical trial that would enroll 50 postpartum women with a history of cocaine abuse or dependence to assess whether progesterone (100mgs twice daily) decreases postpartum cocaine use.
Eligibility Criteria
Inclusion Criteria
- Gravidas (women who delivered a baby in the past 12 weeks) who are 18 or older are eligible to participate.
- Women must meet diagnostic criteria for abuse or dependence of cocaine in the six-months prior to conception or during pregnancy.
- Women who abuse other illicit substances or alcohol would also be eligible as long as cocaine was their primary drug of abuse. If women are also opiate dependent, they must be undergoing treatment with methadone or buprenorphine. While we propose to target cocaine we will also monitor the ability of women with polysubstance use to maintain abstinence from substances other than cocaine.
Exclusion Criteria
Women will be ineligible for the trial if they:
- have a history of major medical illnesses including liver diseases, suspected or known malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke or other medical conditions that the physician investigator deems as contraindicated for participation in the study;
- have a known allergy to progesterone or peanuts (vehicle for micronized progesterone);
- speak a language other than English;
- are planning on moving out of the area in the first six months after delivery;
- are unable to understand the study or are unable to provide informed consent;
- are currently undergoing treatment with another pharmacological agent for substance abuse treatment (with the exception of methadone or buprenorphine as above);
- have pending incarceration;
- are currently incarcerated;
- are using another progestin;
- are unwilling to accept randomization;
- are unwilling to use a barrier method of birth control for the duration of the study to ensure that they will not become pregnant.
Data sourced from ClinicalTrials.gov (NCT01249274). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.